US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Affimed N.V. - Common Stock (NQ:AFMD)

0.1815 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Affimed N.V. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Affimed to Present at the Cantor Global Healthcare Conference 2023
From Affimed N.V.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to start the day off with a breakdown of the biggest pre-market stock movers worth watching on Tuesday morning! 
Via InvestorPlace
News headline image
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
From Affimed N.V.
Via GlobeNewswire
News headline image
Expert Ratings for Affimed ↗
 
Via Benzinga
News headline image
Where Affimed Stands With Analysts ↗
 
Via Benzinga
News headline image
Affimed Earnings Preview ↗
 
Via Benzinga
News headline image
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
From Affimed N.V.
Via GlobeNewswire
News headline image
Surprise! These 3 Penny Stocks Have Wall Street’s Seal of Approval. ↗
While speculative securities are a dime a dozen, these top Wall Street penny stocks offer a measure of confidence for the curious. 
Via InvestorPlace
News headline image
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
News headline image
Analyst Ratings for Affimed ↗
 
Via Benzinga
News headline image
Affimed: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Affimed's Earnings Outlook ↗
 
Via Benzinga
News headline image
3 Cheap Stocks to Buy Under $1 in August 2023 ↗
Penny stocks are risky, but here are three stocks under $1 to buy that are potentially rewarding for bold investors willing to roll the dice. 
Via InvestorPlace
News headline image
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
From Affimed N.V.
Via GlobeNewswire
News headline image
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket ↗
Gainers Forza X1, Inc. (NASDAQ: FRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!' 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start the week off right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
News headline image
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Present at the 2023 Jefferies Healthcare Conference
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
From Affimed N.V.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 23, 2023 ↗
Companies Reporting Before The Bell • ATRenew (NYSE:RERE) is estimated to report quarterly earnings at $0.03 per share on revenue of $405.22 million. 
Via Benzinga
News headline image
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
From Affimed N.V.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday! 
Via InvestorPlace
News headline image
Affimed Announces Annual General Meeting of Shareholders
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
From Affimed N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >